The authors of the new AD withdrawal paper will have serious questions to answer in the coming weeks & months. Their public claims that withdrawal is a non-issue & guidelines must change, are a serious threat to patient safety & public health.... the pushback has not yet begun...

Good to see recognition of Mark Horowitz @markhoro.bsky.social's achievements from the people who matter. A stark contrast with the lack of institutional recognition

I am sure that Sameer Jauhar and co having mis-spoken in their press release will be asking King's College London and Imperial College London and Science Media Centre UK to correct their press releases to reflect the limitations of their data more carefully and not extrapolate to long-term users

Presenting a WEBINAR: Hyperbolic tapering tips: Barriers and enablers with Mark Horowitz, MBBS, PhD lead author of the 2024 Maudsley Deprescribing Guidelines Monday, July 28, 2025 10-11 am PST  |  1-2 p.m EST  |  5-6 pm GMT RSVP today! Donation requested. psychdeprescribing.org/index.php/2025…

Appropriately skeptical reception of the JAMA study down under: "A large systematic review of research into the process of withdrawing from the drugs was published this week, but it quickly faced backlash from some psychiatrists and experts." bit.ly/3U7kpVd

My rapid response in The BMJ hope that uncritical coverage...does not lead to further harm to people suffering from withdrawal...by creating unwarranted complacency amongst clinicians or undermining the small efforts being made by the NHS..." bit.ly/4lL1dbQ

Today we submitted a formal correction request to the editors of JAMA Psychiatry JAMA Psychiatry Dost Öngür in response to the recent Kalfas et al. review, which downplays the risks of antidepressant withdrawal by relying on short-term studies. Our letter outlines the dangerous

"If read uncritically, this new study could cause significant harm by misleading patients, clinicians, guidelines and policy makers." Plain speaking piece from Simon Opher, Labour MP and GP bit.ly/4kDAfSw

starbrewerygallery.com Emma Hames artworks raising awareness of prescribed harm and to help fund her documentary film Toxsick.

New review of my book: 'Though sure to continue challenging people’s ingrained beliefs, it needs to be known. As Vasily Grossman put it, “It is the writer's duty to tell the terrible truth, and it is a reader's civic duty to learn this truth.”' amazon.co.uk/Chemically-Imb…

Lol this is hilarious. The Phillies had a kiss cam and had the Phillie Phanatic re-enact the Coldplay affair😂

"If you have to admit that they are pretty useless, and definitely harmful, then you’ve got to admit to a colossal mistake. And if you add.. that people have been misinformed for decades about the reasons for using them. That’s a huge medical scandal." youtube.com/watch?v=jZqtiu…

I never thought there'd be a day in which I'd be watching Dr. Roger McFillin , Adam Urato, MD , Dr Joanna Moncrieff , Dr. Josef 🇺🇸 , Jeffrey Lacasse , and David Healy speak at the U.S. FDA about the risks of taking SSRIs in pregnancy but here we are. Cheek-pinching moment. What a time of

Had an incredible opportunity to visit the FDA and speak with Commissioner Marty Makary MD, MPH about a critically overlooked issue: how antidepressants—especially when used during pregnancy—can lead to long-term neurological problems in children, including worsening anxiety and

Remember the Henssler review on antidepressant withdrawal, which, once again, mainly focused on short-term trials? - well, here is a powerful rebuttal of that review, led by Dr Joanna Moncrieff & published today 👇 cambridge.org/core/journals/…

I was honoured to take part in the FDA's panel on the risks of SSRIs in pregnancy yesterday chaired by Dr. Marty Makary and Tracy Beth Høeg, MD, PhD. This is a huge issue with so many young women taking these drugs. I hope the UK and other countries will listen x.com/i/broadcasts/1…

🧵1/4 JAMA Psychiatry appears more concerned with petri dishes than real people harmed by antidepressant withdrawal. They’ve denied our request to correct the misleading Kalfas et al. review—a request that was grounded in both the real-world experiences of hundreds of thousands

We received a response today from the NHS. They confirm that they will be updating their NHS website on #RLS to reflect the recent changes to NICE. Dopamine agonists ( #Ropinirole, #Pramipexole & #Rotigotine) will no longer be 1st line meds.